Area of research
Molecular Biology · Oncology
Research interest
Research interests include Protein Degradation and Inhibitors, PARP inhibition in cancer therapy, Prostate Cancer Treatment and Research, and Estrogen and related hormone effects.
Rewiring of cortical glucose metabolism fuels human brain cancer growth
GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress
Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas
Purine metabolism regulates DNA repair and therapy resistance in glioblastoma
Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination
Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy
Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy
Neddylation inactivation represses androgen receptor transcription and inhibits growth, survival and invasion of prostate cancer cells
EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins
Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression
Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
<i>PCAT-1</i> , a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer
Targeted Radiosensitization of ETS Fusion-Positive Prostate Cancer through PARP1 Inhibition